Nm23-H1 nuclear expression is associated with a more favourable prognosis in laryngeal carcinoma: univariate and multivariate analysis

Histopathology. 2012 Dec;61(6):1057-64. doi: 10.1111/j.1365-2559.2012.04331.x. Epub 2012 Sep 17.

Abstract

Aims: To use image analysis and multivariate analysis to investigate the prognostic significance of Nm23-H1 subcellular localization in a large cohort of laryngeal squamous cell carcinomas (LSCCs).

Methods and results: Nm23-H1 total and nuclear levels were immunohistochemically determined and calculated with an image analysis system in 104 consecutively operated LSCCs. The mean follow-up was 58.3 ± 35.1 months (median 45 months). Total Nm23-H1 levels correlated only with patient stratification by pT (P=0.01). Mean nuclear Nm23-H1 levels were lower in patients with recurrent disease (P=0.01), and disease-free survival (DFS) was longer in patients whose nuclear levels of Nm23-H1 were >2.0% than in those with levels ≤ 2.0% (P=0.019). On multivariate analysis, Nm23-H1 nuclear expression [hazard ratio (HR) 2.59, P=0.005] and N stage (HR 3.60, P=0.0001) were prognostically significant in relation to DFS.

Conclusions: In LSCC, Nm23-H1 nuclear expression may be useful for identifying patients at higher risk of recurrence after treatment and who might be considered for more aggressive therapy. Further investigations are needed before Nm23-H1 can be considered for use in targeted treatments for LSCC.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / metabolism*
  • Carcinoma, Squamous Cell / diagnosis*
  • Carcinoma, Squamous Cell / metabolism*
  • Carcinoma, Squamous Cell / mortality
  • Cohort Studies
  • Disease-Free Survival
  • Female
  • Follow-Up Studies
  • Humans
  • Laryngeal Neoplasms / diagnosis*
  • Laryngeal Neoplasms / metabolism*
  • Laryngeal Neoplasms / mortality
  • Male
  • Middle Aged
  • Multivariate Analysis
  • NM23 Nucleoside Diphosphate Kinases / metabolism*
  • Prognosis
  • Recurrence
  • Survival Rate

Substances

  • Biomarkers, Tumor
  • NM23 Nucleoside Diphosphate Kinases
  • NME1 protein, human